Evidence map›Paper›PMID 22102816›Full record

ArticlePLoS pathogens2011

CD11b⁺, Ly6G⁺ cells produce type I interferon and exhibit tissue protective properties following peripheral virus infection.

Matthew A Fischer, Michael L Davies, Irene E Reider, Erica L Heipertz, Melanie R Epler, Janet J Sei, Molly A Ingersoll, Nico Van Rooijen, Gwendalyn J Randolph, Christopher C Norbury

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 64 citations in OpenAlex.

  1. A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Mpox (formerly monkeypox): pathogenesis, prevention, and treatment.Signal transduction and targeted therapy · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Healing Mechanisms in Cutaneous Wounds: Tipping the Balance.Tissue engineering. Part B, Reviews · 2022
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Matthew A FischerDepartment of Microbiology and Immunology, Pennsylvania State University Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States of America.
Michael L Davies
Irene E Reider
Erica L Heipertz
Melanie R Epler
Janet J Sei
Molly A Ingersoll
Nico Van Rooijen
Gwendalyn J Randolph
Christopher C Norbury
Penn State Milton S. Hershey Medical Center · USPennsylvania State University · USIcahn School of Medicine at Mount Sinai · USVrije Universiteit Amsterdam · NL

Funding

The innate Immune Response to Mousepox at the Site - Associated ProjectU19AI083008 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI NORBURY, CHRISTOPHER C · 2009 to 2013
$9.6M
Pathways of Antigen Presentation to CD8 T Cells In VivoR01AI056094 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI NORBURY, CHRISTOPHER C · 2003 to 2013
$3.1M
Leukotrienes in Innate and Adaptive Antiviral ImmunityR01AI070537 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI NORBURY, CHRISTOPHER C · 2006 to 2009
$1.4M
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR015428 · NCRR · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI EVARTS, C M · 2000 to 2000
$1.1M
NCRR NIH HHS C06 RR015428NCRR NIH HHS C06 RR-15428NIAID NIH HHS R01 AI056094NIAID NIH HHS R01 AI070537NIAID NIH HHS U19 AI083008
6 · The paper itself

Abstract

The goal of the innate immune system is containment of a pathogen at the site of infection prior to the initiation of an effective adaptive immune response. However, effector mechanisms must be kept in check to combat the pathogen while simultaneously limiting undesirable destruction of tissue resulting from these actions. Here we demonstrate that innate immune effector cells contain a peripheral poxvirus infection, preventing systemic spread of the virus. These innate immune effector cells are comprised primarily of CD11b⁺Ly6C⁺Ly6G⁻ monocytes that accumulate initially at the site of infection, and are then supplemented and eventually replaced by CD11b⁺Ly6C⁺Ly6G⁺ cells. The phenotype of the CD11b⁺Ly6C⁺Ly6G⁺ cells resembles neutrophils, but the infiltration of neutrophils typically occurs prior to, rather than following, accumulation of monocytes. Indeed, it appears that the CD11b⁺Ly6C⁺Ly6G⁺ cells that infiltrated the site of VACV infection in the ear are phenotypically distinct from the classical description of both neutrophils and monocyte/macrophages. We found that CD11b⁺Ly6C⁺Ly6G⁺ cells produce Type I interferons and large quantities of reactive oxygen species. We also observed that depletion of Ly6G⁺ cells results in a dramatic increase in tissue damage at the site of infection. Tissue damage is also increased in the absence of reactive oxygen species, although reactive oxygen species are typically thought to be damaging to tissue rather than protective. These data indicate the existence of a specialized population of CD11b⁺Ly6C⁺Ly6G⁺ cells that infiltrates a site of virus infection late and protects the infected tissue from immune-mediated damage via production of reactive oxygen species. Regulation of the action of this population of cells may provide an intervention to prevent innate immune-mediated tissue destruction.

Indexed as

Immunity, InnateAnimalsAntigens, LyCD11b AntigenInterferon Type IMacrophagesMiceMice, Inbred C57BLMice, KnockoutMonocytesNeutrophilsReactive Oxygen SpeciesVacciniaVaccinia virusAntigens, LyCD11b AntigenInterferon Type ILy6G antigen, mouseReactive Oxygen Species

Identifiers

PMID22102816
PMCPMC3213107
OpenAlexW1969741581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.